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Abstract
Background:  In von Hippel-Lindau (VHL) disease, germline mutations in the VHL tumor
suppressor gene cause clear cell renal carcinomas, hemangioblastomas, and pheochromocytomas.
The VHL gene product is part of an ubiquitin E3 ligase complex and hypoxia-inducible factor alpha
(HIF-α) is a key substrate, although additional VHL functions have been described. A genotype-
phenotype relationship exists in VHL disease such that specific VHL mutations elicit certain subsets
of these tumors. Here, we examine VHL genotype-phenotype correlations at the cellular level,
focusing on the regulation of tight junctions and cell morphology.
Methods: Wild-type and various mutant VHL proteins representing VHL disease subtypes were
stably expressed in 3 VHL-negative renal carcinoma cell lines. Using these cell lines, the roles of
various VHL-associated cellular functions in regulation of cell morphology were investigated.
Results: As a whole, type 1 mutants varied greatly from type 2 mutants, demonstrating high levels
of HIF-2α, cyclin D1 and α5 integrin, lower p27 levels, and a spindly, fibroblastic cellular
appearance. Type 2 mutations demonstrated an epithelial morphology similar to wild-type VHL in
the majority of the renal cell lines used. Knockdown of p27 in cells with wild-type VHL led to
perturbations of both epithelial morphology and ZO-1 localization to tight junctions. ZO-1
localization correlated well with VHL disease subtypes, with greater mislocalization observed for
genotypes associated with a higher risk of renal carcinoma. HIF-2α knockdown in 786-O partially
restored ZO-1 localization, but did not restore an epithelial morphology.
Conclusion: VHL has both HIF-α dependent and HIF-α independent functions in regulating tight
junctions and cell morphology that likely impact the clinical phenotypes seen in VHL disease.
Background
von Hippel-Lindau (VHL) disease is a relatively rare fam-
ily cancer syndrome, affecting one in 36,000 people [1].
Individuals afflicted with von Hippel-Lindau disease are
predisposed to different subsets of tumors, including phe-
ochromocytomas, hemangioblastomas, and renal cell car-
cinomas (reviewed in [2]). Inactivation of the VHL tumor
suppressor gene is responsible for both the hereditary
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tumors in VHL disease as well as sporadic renal carcino-
mas and hemangioblastomas [3-8], (reviewed in [9]).
The VHL tumor suppressor gene resides on chromosome
3p25 and consists of three exons (reviewed in [10]). The
VHL gene product exists in two major isoforms: full length
pVHL30 and the smaller pVHL19, which results from inter-
nal translation of the VHL mRNA from an in-frame start
codon [11-13]. Reintroduction of either VHL product into
VHL null cells inhibits in vivo tumor formation, signifying
that both contain tumor suppressor functions [11-13].
VHL gene products (collectively called pVHL) are part of
an ubiquitin E3 ligase complex, together with elongin B,
elongin C, cullin 2 (Cul2), and Rbx1, that covalently
attaches ubiquitin on substrates, targeting them for pro-
teasomal degradation [14-19]. One target substrate that
has been overwhelmingly confirmed for the pVHL E3
ubiquitin ligase complex is hypoxia-inducible factor
alpha (HIF-α) [20-23]. HIF-α is stabilized in low oxygen
environments and forms a heterodimer with HIF-β, which
binds to hypoxia-responsive elements in the promoters of
hypoxia-inducible genes (reviewed in [24]). The presence
of oxygen is required for the hydroxylation of key proline
residues on HIF-α, which allows for its recognition by
pVHL and its subsequent ubiquitination [25-27].
VHL disease has a strong genotype-phenotype correlation
and specific mutations associated with VHL disease have
been categorized by clinical subtypes of incidence of spe-
cific tumor types (reviewed in [2]) (see Table 1). Type 1
VHL mutations are mostly deletions and truncation muta-
tions that drastically alter pVHL and phenotypically man-
ifest in a low occurrence of pheochromocytoma and high
frequency of renal cell carcinoma [28,29]. Type 2 muta-
tions are commonly missense mutations and manifest in
a high occurrence of pheochromocytoma. Subtypes of
type 2 VHL disease depend on incidence of other tumors,
namely hemangioblastomas and renal cell carcinoma
(RCC). Type 2A disease is associated with a high incidence
of pheochromocytoma, hemangioblastoma, and low inci-
dence of RCC. Type 2B disease exhibits a high incidence
of pheochromocytoma, hemangioblastoma, and RCC.
Type 2C disease has pheochromocytoma, but not heman-
gioblastoma and RCC. Disparities among the pVHL
mutants in their ability to ubiquitinate HIF-α (through
deficiencies either in HIF-α binding or in ability to form a
functional E3 ligase complex) have been suggested to
underlie the differences in tumor risks among the VHL
disease subtypes [22,30-32]. Accordingly, there has been
support for the notion that both the higher RCC incidence
seen with type 2B and type 1 VHL mutations and the lack
of pheochromocytoma in type 1 mutants may be a result
of higher HIF-α levels [33,34].
There is increasing evidence that ubiquitination of HIF-α
is necessary for VHL-dependent suppression of tumor
progression [35-38]. However, there are also several func-
tions related to VHL, such as assembly of extracellular
matrix, formation of β1-integrin adhesions, regulation of
integrin levels, stability of microtubules, organization of
intercellular junctions, maintenance of cellular polarity
Table 1: VHL mutant constructs used in this study
Clinical phenotype (risk of tumor type)
Mutant VHL Subtype Pheo Hemangio RCC References
del 114–178 1 - ++ ++ [11,53]
RC161/2QW 1 [53]
S65W 1 [29,58,59]
N78S 1 [28,29]
L158P 1 [29]
L188Q 1 [29]a
Y98H 2A ++ ++ - [29,60,61]
Y112H 2A [28,29,62]
Y98N 2B ++ ++ ++ [4,63]a
Y112N 2B [63]
R167Q 2B [29,58,64,65]
R167W 2B [28,29,58,64,65]
V84L 2C ++ - - [66]a
L188V 2C [28,61,67]
Pheo, pheochromocytoma; hemangio, hemangioblastoma; RCC, renal cell carcinoma
a subtype designation based on a small familyBMC Cancer 2009, 9:229 http://www.biomedcentral.com/1471-2407/9/229
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and cell morphology, cell differentiation, and inhibition
of autophagy, for which the relationship to HIF are either
currently unclear or may be independent of HIF-α ubiqui-
tination/degradation [39-49]. Along these lines, nonfunc-
tional VHL has been shown to disrupt intercellular
junctions in an HIF-independent manner [44]. However,
other studies have indicated that such intracellular junc-
tions may be influenced by HIF and/or hypoxia [50,51],
indicating a need for clarification of the role of HIF in this
VHL-associated phenotype.
In this study, we introduced a spectrum of VHL mutant
constructs covering the range of disease phenotypes into
several VHL-null renal cell lines and focused on the effects
of these mutations on tight junction formation and cell
morphological changes. Various VHL target proteins were
assessed to determine their roles in these VHL-dependent
morphology changes. We report here that there was a stark
contrast between type 1 and type 2 VHL mutants in their
HIF-α status, levels of integrins and cell cycle proteins,
tight junctions, and cell morphology. In particular, loss of
VHL roles in suppression of integrin levels and regulation
of tight junction formation correlated with VHL disease
subtypes and are likely to play a part in initiation of renal
tumorigenesis.
Methods
Cell lines and cell culture
Renal cell lines (293T, 786-O, and A498) were obtained
from the American Type Culture Collection, whereas
RCC10 renal carcinoma cells were provided by Miguel
Esteban (Imperial College, London). All cells were grown
in Dulbecco's modified Eagle's medium containing 10%
Serum Supreme (BioWhitaker) and penicillin-streptomy-
cin (100 U/ml and 10 μg/ml, respectively). 786-O cells
stably transfected with pVHL19, or infected with control
pSuperRetro retroviruses or with retroviruses directing
expression of short hairpin RNA's (shRNA) targeting HIF-
2α [35] that were provided by Dr. William Kaelin (Dana
Farber Cancer Center), have been described previously
[47]. For growth on collagen I, cells were grown on com-
mercially prepared culture plates coated with a thin layer
of collagen I (Becton Dickinson).
Generation of VHL mutants
Mutant VHL sequences were either created de novo by
sequential PCR steps using overlapping primers contain-
ing the desired point mutation, as previously described
[11,52], or PCR amplified from existing VHL mutant con-
structs [11,53]. In creating pVHL30 expression constructs,
mutant and wild-type (WT) VHL sequences from existing
constructs or from PCR products (produced in the first
step of de novo sequential PCR) were PCR amplified using
the forward primer 5'GCGCGCGGATCCGCCACCAT-
GCCCCGGAGGGCGGAGAACTGGGAGC 3' and reverse
primer 5' CCCGGGCTCGAGTCAATCTCCCATCCGTT-
GATGTGCAATGC 3' (underlined sequences represent
BamHI and XhoI restriction sites respectively). Wild-type
and mutant pVHL19  sequences were similarly created,
except the forward primer 5'GCGCGCGGATCCGCCAC-
CATGGAGGCCGGGCGGCCGCGGCCCGTGC 3' was
used in PCR amplifications.
Retroviral expression constructs
PCR products containing wild-type (WT) and mutant
pVHL30 coding sequences (as described above) were direc-
tionally cloned into the BamHI/XhoI sites in a pBabe-
derived retroviral expression construct [54]. An empty
plasmid (same pBabe-derived retroviral expression con-
struct containing no VHL insert) was used as a control.
PCR products containing wild-type and mutant pVHL19
coding sequences were cloned into BamHI/XhoI sites that
were engineered into another retroviral vector, pQCXIP
(Clontech, Mountain View, CA). The empty pQCXIP vec-
tor was used as a control for this series of mutant plas-
mids. To create a shRNA construct targeting p27, the
oligonucleotides gatccccTGGTGATCACTCCAGGTAGt-
tcaagagaC TACCTGGAGTGATCACCAtttttggaaa and agc
ttttccaaaaaTGGTGATCACTCCAGGTAGtctcttgaaCTACCT-
GGAGTGATCACCAggg (capital letters indicate RNA inter-
ference target sequences) were annealed and ligated into
the BglII/HindIII sites in the vector pSuperRetro [55]. A
shRNA construct targeting luciferase has been previously
described [54]. All constructs were confirmed by DNA
sequencing and/or restriction enzyme digestion.
Transfections, Retroviral Production and Infection
To produce retroviral supernatants, each retroviral vector
was co-transfected with the retroviral packing plasmid,
pCL-Ampho [56], into 293T cells in 35 mm dishes using
Lipofectamine Plus reagent (Invitrogen) as directed by the
manufacturer. 293T cells from each transfection were
replated into 60-mm dishes. Medium containing retrovi-
ruses was collected at 72 h post-transfection and filtered
through a 45 μm pore-size filter. To create stable pools of
retrovirally infected cells, parental RCC10 and A498 cells
were incubated overnight in a mixture (1:1) of retroviral
supernatant and fresh medium supplemented with poly-
brene (10 μg/ml). Three days later, cells were selected with
puromycin (0.5 μg/ml) for 10 to 14 days. For stable pools
of cells transfected with VHL expression plasmids, cells
were transfected in 35 mm dishes using Lipofectamine
Plus reagent. Cells were replated in 60-mm dishes (per-
formed 2–16 hours post transfection), selected three days
post-transfection with puromycin (0.5 μg/ml) for 10 to 14
days, and surviving cells were pooled.
Western blotting
For all immunoblots, cells were grown to 100% conflu-
ency. 60 mm culture plates were rinsed with phosphateBMC Cancer 2009, 9:229 http://www.biomedcentral.com/1471-2407/9/229
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buffer saline (PBS) and cells were lysed using 150 to 175
μl of lysis buffer (50 mM HEPES (pH 7.6), 250 mM NaCl,
0.5% Nonidet P-40, 0.5% Triton X-100, 5 mM EDTA, 1
mM phenylmethylsulfonyl fluoride (PMSF), 1 mM
Na2VO3 and 2 μg/ml each of aprotinin, bestatin, and leu-
peptin), incubating at 4°C for 30 minutes. Lysed cells
were scraped with a plastic scraper, resuspended by pipet-
ting, collected and then microcentrifuged for 15 minutes.
Supernatants containing clarified protein lysates were
removed and protein levels were determined by Bradford
assay (Bio-Rad). Equal amounts (25–50 μg) of protein
lysates were added to an appropriate amount of 2× SDS
PAGE loading buffer and resolved by SDS-polyacrylamide
gel electrophoresis and subsequently transferred to a pol-
yvinylidene difluoride (PVDF) membrane overnight.
Quantification of bands on western blots (using the anti-
bodies below) was performed with Image J software (ver-
sion 1.39 u).
Antibodies
Rabbit polyclonal anti-HIF-2α antibody was from Novus
Biological. Rabbit anti-GLUT-1 antiserum was from Alpha
Diagnostics. Anti-VHL mAb 11E12 has been previously
described [11]. Integrin and p27 mAbs were obtained
from BD Transduction Laboratories. Rabbit Cyclin D1
antibody was from Santa Cruz Biotechnology. Rabbit
anti-ZO-1 (Mid) was from Zymed. Anti-alpha tubulin
mAb, as well as HRP-conjugated rabbit and mouse sec-
ondary antibodies were from Sigma. Texas red-conjugated
goat anti-rabbit secondary antibody was from SouthernBi-
otech.
Phase and Immunofluorescence Microscopy
For phase-contrast analysis of cell morphology, cells were
grown on 60-mm collagen I coated plates until conflu-
ence and viewed on an Axiovert S100 microscope, with
images captured by a Nikon DS-Fi1 CCD digital camera.
For immunofluorescence experiments, cells were grown
on coverslips in 6-well plates until they reached conflu-
ence. Cells were rinsed with PBS and then fixed and per-
meabilized by 1 min incubation in methanol/acetone
(1:1) at -20°C and then rehydrated/washed twice for 3
min with PBS. Coverslips were incubated with blocking
solution (1% goat serum in PBS containing 0.1% Tween-
20) for 1 hr and then incubated with anti-ZO-1 antibody
diluted 1:90 in blocking solution for 1 hr. Coverslips were
washed (with rocking) 3 times for 5 min each with PBS
containing 0.1% Tween-20 and then incubated for 1 hr
with Texas Red-conjugated secondary antibody diluted
1:100 in blocking solution. Cells were washed 3 times as
previously except that during the second wash, 4',6-dia-
midino-2-phenylindole (DAPI) was added at a concentra-
tion of 0.25 μg/ml. Cells were rinsed with PBS, mounted
on slides with GelMount, and viewed at a magnification
of 1000× on a Zeiss Axioskop microscope, with images
collected by a Spot Insight QE digital camera. Random
fields containing approximately equal numbers of nuclei
(to eliminate any possible effects of confluency) were
selected for viewing and exposures during imaging were
kept constant for all samples (14 sec and 2 sec for ZO-1
and DAPI, respectively) to allow for more direct compari-
sons.
Cycloheximide VHL Stability Assay
Each cell line was grown to confluence in 3 wells of 6-well
culture dishes. Cells were then either left untreated or
treated with cycloheximide (100 μg/ml; Sigma) for vari-
ous time points and then lysed and assayed by western
blotting as described previously.
Results
Type 1 VHL mutants have upregulated HIF-2α and 
downregulated p27
In order to investigate the cellular effects of specific VHL
mutations, a set of mutant (and wild type) VHL retroviral
expression constructs was created. Naturally occurring dis-
ease-associated mutations were chosen to represent all of
the VHL disease subtypes based on information in the
VHL mutation database [57], with 2 larger-scale rear-
rangements that were previously demonstrated to have a
more complete inactivation of VHL function [11,53].
Note that while most of the mutations utilized here have
been described in multiple VHL families, a few of the
mutations (used here and in other reports) are not espe-
cially common and have been classified based on a single
family. A list of all VHL mutations employed in this study
(with references) can be found in Table 1 and are repre-
sented diagrammatically in Figure 1A. (References indi-
cated in Table 1 are [4,11,28,29,53,58-67]). The mutant
VHL expression constructs were used to generate several
panels of cell lines that are described throughout this
report.
Initially, VHL-negative RCC10 and A498 cells were
infected with retroviruses directing expression of either
wild type or mutant pVHL30 proteins or as a control, an
empty vector retrovirus. In RCC10 cells (Figure 1B), type
1 VHL mutants were represented by constructs coding for
pVHL with a deletion of amino acid residues 114 to 178
(del 114–178), a double point mutant RC161/2QW, the
L188Q mutation, as well as control cells infected with a
retrovirus lacking any VHL sequence. Type 2 VHL muta-
tions included type 2A (Y98H), type 2B (Y98N, R167W,
and R167Q), and type 2C mutations (L188V and V84L).
A subset of these constructs was similarly infected into
A498 cells (Figure 1C). For each infection, a stable pool
(hereafter referred to as a cell line) was generated after
puromycin selection. Western blots were performed to
verify pVHL expression (Figure 1B and 1C, top panels)
and HIF-2α levels (Figure 1B and 1C, second panels) in
these cell lines. Cells expressing the type 1 VHL mutations
(control, del 114–178, RC161/2QW, and L188Q)BMC Cancer 2009, 9:229 http://www.biomedcentral.com/1471-2407/9/229
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expressed high or intermediate levels of HIF-2α. However,
low levels of HIF-2α similar to those observed with wild-
type VHL were seen with all of the type 2 mutations
(Y98H, Y98N, R167Q, R167W, L188V, and V84L) in this
system. Levels of glucose transporter 1 (GLUT-1), a tran-
scriptional target of HIF, were concomitantly upregulated
in cell lines with type 1 VHL mutant proteins (Figure 1B
and 1C, third panels).
Several proteins were assayed as markers of VHL cellular
functions (Figure 2A and 2B). For these analyses, cells
were grown to confluence on collagen I because VHL-
dependent effects on cell cycle and morphology have been
shown to be more apparent under these conditions, even
with standard serum levels in the culture medium
[39,42,47]. Integrins are cell-extracellular matrix (ECM)
adhesion proteins that are associated with cell morpho-
logical changes, are often upregulated in RCC cells that are
more motile and invasive, and have been shown to be
downregulated by pVHL in an HIF-independent manner
[42,47,48]. In our cell lines, type 1 VHL mutants (control,
del 114–178, and RC161/2QW, and to a lesser extent
L188Q) expressed higher levels of α5 integrin (Figure 2A
and 2B, top panels). In the RCC10 cell lines, β1 integrin
levels were somewhat less variable, however the general
trend of higher expression in type 1 mutant cells was
upheld (Figure 2A, second panel). In contrast, wild-type
and all type 2 VHL mutant cell lines had lower levels of
these integrins (Figure 2A, top and second panels and Fig-
ure 2B, top panel).
Previous studies had indicated that pVHL expression
affects levels of levels of cyclin D1 and the cyclin-depend-
ent kinase (cdk) inhibitor, p27 [68-71]. Thus, the cell
cycle status in our panels of mutant cells grown on colla-
gen I was analyzed via western blots for cyclin D1 (Figure
2A, third panel and Figure 2B, second panel) and p27
(Figure 2A, fourth panel and Figure 2B, third panel). Type
1 mutant cells that had high HIF-2α levels (control, del
114–178, and RC161/2QW) expressed high levels of cyc-
Type 1, but not type 2 VHL mutants are grossly deficient in HIF-2α regulation Figure 1
Type 1, but not type 2 VHL mutants are grossly deficient in HIF-2α regulation. (A) Diagrammatic representation of 
pVHL, with first and last amino acid residues in bold. Codon 54 represents the start of the pVHL19 product. Mutations used in 
this study and location of the α and β domains in the reported VHL structure [84] are shown. The location of the elongin bind-
ing domain is demarcated with a black box. (B) RCC10 VHL-null cells were stably infected with retroviruses produced with the 
empty vector with no VHL insert (control) or with wild-type (WT) or mutant pVHL30 expression constructs, as indicated. 
Cells were grown to confluence and prepared cell lysates were equally loaded and separated by SDS-PAGE. Western blots 
were performed for VHL, HIF-2α, and GLUT-1. Note that the 3 bands observed for VHL are closely-migrating isoforms of 
pVHL30 [11], but are not pVHL19, which was not produced by these constructs (data not shown). α-tubulin was also assayed to 
demonstrate equal loading. *indicates decreased size of VHL deletion protein. (C) A498 VHL-null cells were similarly stably 
infected and the resulting cell lines were analyzed by western blotting.
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lin D1, indicating more active cell cycling. All other cell
types, including all containing type 2 VHL mutants, dem-
onstrated low levels of cyclin D1 equivalent to cells with
wild-type VHL, suggesting proper pVHL functioning in
regulating cell cycle exit. In RCC10, type 1 control, del
114–178, and RC161/2QW cells also displayed low levels
of p27 expression, which correlated to their high levels of
cyclin D1 and further signifies a deregulation of cell cycle
exit in these cells. Again, all other RCC10 cells (including
all type 2 VHL mutants) showed normal expression of p27
as compared to those with wild-type VHL, demonstrating
their ability to properly exit the cell cycle. Interestingly,
the type 1 mutant L188Q, which had only slightly ele-
vated levels of HIF-2α, demonstrated neither cyclin D1
upregulation nor downregulation of p27, suggesting that
either only high HIF-2α levels are associated with these
phenomenon or that they are independent of HIF-2α sta-
tus. Surprisingly, the A498 cell line did not behave like
RCC10 cells, with no stark differences in p27 levels seen
among cell lines expressing wild-type or mutant VHL pro-
teins (Figure 2B, third panel). This result may be due to
differences in the set of acquired mutations that these cells
have gained following VHL loss or due to other intrinsic
variations among these cells. Importantly, the lack of p27
effect on A498 cells occurred in spite of differences in HIF-
2α regulation among the cell types, indicating that p27
expression is not likely to be directly regulated by HIF.
Knockdown of p27 disrupts epithelial morphology and 
tight junction formation
Since the type 1 VHL mutant cell lines were strikingly dif-
ferent than the type 2 lines with respect to HIF-2α, GLUT-
1, integrin, cyclin D1, and (in RCC10) p27 levels, we
looked at whether there was any correlation between the
levels of these proteins and the morphology of these cells.
Images of the cells were captured upon confluent growth
on collagen I. In RCC10, type 1 VHL cell lines that had
high HIF-2α and low cyclin p27 (control, del 114–178,
and RC161/2QW) had a more disorganized, fibroblastic
phenotype whereas wild-type VHL and all of the type 2
cell lines displayed a more organized epithelial-like mor-
phology (Figure 3A and Table 2). In line with the lack of
effect of VHL expression on p27 levels in A498 (as seen in
Figure 2B), VHL expression had no effect on the morphol-
ogy of A498 cells, with VHL-negative, wild-type VHL, and
all VHL mutant cell lines demonstrating a disorganized
fibroblastic phenotype (Figure 3B). Thus, proper VHL-
mediated upregulation of p27 (or conversely, downregu-
lation of p27 due to acute VHL loss) appears to be associ-
ated with cell morphological changes.
To further explore the relationship of p27 and cell mor-
phology, a retroviral short hairpin RNA construct
(shRNA) targeting p27 was created and used to infect the
wild-type pVHL30-expressing RCC10 cell line. In compar-
ison to control infected cells (infected with a shRNA tar-
geting the non-human protein luciferase), the p27 shRNA
efficiently knocked down p27 levels in these wild-type
VHL cells (Figure 4A) and moreover, disrupted the epithe-
lial morphology of these cells (Figure 4B).
Intracellular junctions such as adherens and tight junc-
tions are known to greatly influence cellular morphology,
and loss of both of these junctions is a characteristic of the
Differential regulation of key markers of VHL function by type 1 and type 2 VHL mutants Figure 2
Differential regulation of key markers of VHL function by type 1 and type 2 VHL mutants. (A) Indicated RCC10 
cell lines were grown to confluence on collagen I (under standard serum conditions) and prepared cell lysates were equally 
loaded and separated by SDS-PAGE. Western blots were performed for α5 and β1 integrins, cyclin D1, p27, and α-tubulin. 
VHL subtypes that mutations represent are provided at the top. Quantification of the band intensities for p27 blot (as a per-
cent of the band with greatest intensity) is provided at the bottom. (B) A498 cells lines were similarly grown and analyzed by 
western blotting. VHL subtypes that mutations represent are provided in parentheses.
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epithelial-to-mesenchymal transition that accompanies
tumor formation [72]. While a clear role of VHL in main-
tenance of adherens junctions has been established
[50,73], VHL has also been previously shown to regulate
tight junction complexes [44,74]. To determine whether
the morphological effect that we observed with p27
knockdown occurs via disruption of tight junctions, fluo-
rescent immunostaining of ZO-1, an important member
of tight junction complexes, was performed. Whereas the
control infected wild-type VHL cells showed ZO-1 stain-
ing in regions of cell-cell contact, forming rings of ZO-1
indicative of well-polarized cells, knockdown of p27 had
a drastic effect on ZO-1 localization, with very little ZO-1
seen at cell-cell junctions (Figure 4C). These data indicate
that regulation of p27 by VHL in RCC10 cells is necessary
for proper tight junction formation.
To assess whether this phenomenon occurs in other VHL
cell systems, we repeated the p27 knockdown using 786-
O cells (a VHL-negative RCC cell line) in which the
pVHL19 protein was stably reintroduced and expressed
[11,47]. Knockdown of p27 in these cells led to diminu-
tion of ZO-1 staining (Figure 4D and 4E), albeit not to the
extent seen with p27 knockdown in pVHL30-containing
RCC10 cells. The reason for the difference between cell
lines is not clear and suggests that p27 levels influence,
but perhaps are not the sole determinant of tight junction
formation in VHL-positive RCC cells.
Lack of difference in cell morphology among type 2 VHL 
mutants is not due to the mechanism of VHL 
reintroduction
While our data indicated that type 1 VHL mutants differ
from type 2 mutants, especially with respect to cell mor-
phology, we had seen very little difference among the type
2 mutations. Since previous studies had indicated that
type 2B VHL mutants are more defective in HIF-α regula-
tion than type 2A mutants [30,34], we wished to deter-
mine whether the retroviral infections that we utilized,
which can introduce multiple copies of the expression
construct, might be influencing our results. Toward this
end, we transfected RCC10 cells with our pVHL30 con-
structs, selected with puromycin, and generated pools of
stable transfectants (Figure 5A). For these experiments, we
utilized paired mutations with alternate amino acids at
the same VHL codon that result in different VHL disease
subtypes, based on the notion that they may reveal differ-
ences in VHL biochemical functions that are relevant to
differential tumor risk. While upregulated HIF-2α and
GLUT-1 were seen with type 1 mutant L188Q and with
the type 2B mutant Y98N (as compared to wild-type VHL
and type 2A mutant lines), the type 2B mutant Y112N cell
line did not demonstrate this effect, suggesting that the
currently accepted division of VHL subtypes does not per-
fectly conform to the status of HIF-α regulation. Of note,
all of the transfected type 2 VHL cell lines demonstrated
an epithelial morphology including the type 2B mutants
(Table 2), indicating that method of VHL reintroduction
was not a factor in this phenotype. However, our data
leaves open the possibility that very high levels of HIF-2α
(as seen with almost all of the type 1 VHL mutants) are
associated with a lack of epithelial morphology.
Type 1 mutant VHL proteins are unstable
Since the majority of the type 1 VHL mutations utilized so
far in our assays were major alterations in pVHL, addi-
tional type 1 VHL mutations, all missense (S65W, N78S,
and L158P), were studied (Figure 5B). The new RCC10
mutant cell lines were generated by retroviral infection as
previously. All of these additional type 1 VHL mutant
RCC10 cell lines showed upregulated HIF-2α and GLUT-
1, although the S65W mutant had slightly lower, but still
upregulated HIF-2α. As expected, all of the new missense
type 1 VHL mutant cell lines displayed the same disorgan-
ized, fibroblastic morphology as seen with the other type
1 VHL mutants (Table 2).
RCC10 cells with type 1, but not type 2 mutant VHL pro- teins lack an epithelial-like morphology Figure 3
RCC10 cells with type 1, but not type 2 mutant VHL 
proteins lack an epithelial-like morphology. (A) Indi-
cated RCC10 cell lines were grown to confluence on colla-
gen I and photographed by digital phase microscopy (original 
magnification of 100×). Note the disorganized morphology of 
the control and the VHL del 114–178 and RC161/2QW-
expressing cells. (B) A498 cell lines were similarly analyzed by 
phase microscopy. Note that all of the A498 cell lines display 
a disorganized non-epithelial phenotype.
control del 114-178 
L188V
RC161/2QW
Y98H WT
control del 114-178 RC 161/2QW
WT Y98H L188V
A
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The S65W mutant cell line was interesting in that the level
of VHL protein was considerably lower than for all other
mutants. Since the 5' regions were identical for all of the
expression constructs used, this finding suggested that
there are differences in the stability of the various VHL
mutants. In fact, many of the type 1 VHL mutants
expressed in these studies showed slightly lower levels of
pVHL expression (see Figures 1B, and 1C, and Figure 5A).
To further investigate, a cycloheximide stability assay was
performed, focusing on the type 1 VHL missense muta-
tions. RCC10 cell lines were treated with cycloheximide
for given amounts of time and levels of VHL protein were
assayed by western blotting (Figure 6). All of the type 1
missense mutants tested (L188Q, S65W, N78S, and
L158P) were unstable, with no detectable protein seen
after 2 hours (or 2.5 hours in the case of L188Q) of
cycloheximide. Since both transfected and infected cell
lines were utilized (Figures 6A and 6B), this effect was also
independent of the mechanism in which VHL was
replaced in these cells. In accord with a previous observa-
tion that elongin B and C binding to pVHL confers stabil-
ity and that mutations in the elongin binding domain
render VHL proteins unstable [53], the type 2B mutant
R167Q was relatively unstable in the assay reported here,
with slightly detectable levels of VHL protein after 2 hours
of cycloheximide treatment. However, other type 2B VHL
mutations containing mutations outside of the elongin
binding domain (Y98N and Y112N) were much more sta-
ble, indicating that the instability of the R167Q mutant is
not indicative of the entire 2B VHL subtype. We also noted
that the abundance of faster migrating pVHL30 isoforms
for any particular VHL mutant (see bottom arrows for
VHL in Figure 6) was a predictor of VHL stability, since
those VHL mutant proteins that produced lower levels of
these faster migrating isoforms (type 1 mutations and
R167Q) were the least stable in our assay. The significance
of this finding is currently unclear, but may have func-
tional implications.
Lack of morphological change by type 1 VHL mutations is 
recapitulated in 786-O cells
Since the results of morphological analyses performed
thus far in this study had relied on the RCC10 cell line, we
wished to extend these findings to another VHL-negative
cell line, 786-O. We generated a panel of 786-O cells as
previously, with the following exceptions: 1) VHL and
control expression constructs were transfected rather than
selected into these cells; 2) pVHL19 expression constructs
were used (rather than pVHL30); and 3) a different expres-
sion vector was utilized (see Methods). Analysis of pro-
teins associated with VHL function was similar to those
seen with pVHL30 in RCC10 cells, with upregulated HIF-
2α, GLUT-1, and cyclin D1 detected in most of the type 1
VHL mutant lines (control, RC161/2QW and del 114–
178) and partial upregulation seen with L188Q (Figure
7A). Differences in p27 abundance in 786-O were much
more subtle and only partially recapitulated the pattern
seen in RCC10 (data not shown). Note that PTEN is inac-
tivated in 786-O [75], which is likely to affect p27 regula-
tion in this cell line.
Table 2: Summary of analyses of RCC10 and 786-O cell lines.
Cell Line Subtype Epithelial Morphologya VHL Instability Aberrant ZO-1
RCC10 786-O
Wild-type - + + - -
control 1 - - +++
del 114–178 1 - - +b ++
RC161/2QW 1 - - +b +++
S65W 1 - N/D + ++
N78S 1 - N/D + ++
L158P 1 - N/D + +++
L188Q 1 +/- + + +++
Y98H 2A + + - -
Y112H 2A + + - N/D
Y98N 2B + + +/- +
Y112N 2B + + - N/D
R167Q 2B + +/- + ++
R167W 2B + + +b N/D
V84L 2C + + N/D N/D
L188V 2C + + - -
a – indicates a disorganized fibroblast-like morphology
+/- indicates that an intermediate morphology was observed
b previously demonstrated in [53]
N/D = not determinedBMC Cancer 2009, 9:229 http://www.biomedcentral.com/1471-2407/9/229
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In contrast to the other markers studied, α5 integrin levels
seemed to correlate closely with VHL disease subtype in
786-O cells, with the lowest levels seen with wild-type
VHL, slightly elevated levels seen with type 2A and 2C
VHL mutants (2A: Y98H, Y112H; 2C: V84L), higher levels
seen with a majority of the type 2B VHL mutants (R167Q,
Y112N, Y98N) and still higher levels in the type 1 VHL
mutants. Cell morphological analyses in 786-O yielded
very similar to results as in RCC10, with type 1 control,
RC161/2QW and del 114–178 cell lines demonstrating a
fibroblastic, disorganized phenotype and all other cells
displaying an epithelial phenotype, with the exception of
the R167Q mutant, which had an intermediate morphol-
ogy (Figure 7B). The L188Q mutant, which had shown an
intermediate phenotype in RCC10, was seen to be some-
what more epithelial in 786-O. The results of the morpho-
logical analyses with both RCC10 and 786-O cell lines are
summarized in Table 2.
Tight junctions are severely compromised in type 1 VHL 
mutants
We next wanted to look at differences in the formation of
tight junctions among the VHL mutant cell lines. The
panel of RCC10 cells was immunostained for ZO-1 (Fig-
ure 8). Cells with wild type or type 2C or 2A VHL mutants
(L188V or Y98H, respectively) demonstrated adequate
ZO-1 staining at all cell-cell borders. Some disorganized
ZO-1 staining (e.g., entire borders not stained) was seen
with the type 2B VHL mutants, Y98N and to a slightly
greater extent, R167Q. An overall more disorganized ZO-
1 staining pattern (with staining largely absent from the
majority of cell-cell junctions) was seen with type 1 VHL
mutants (L188Q, control, del 114–178, RC161/2QW,
S65W, N78S, and L158P). The results of the tight junction
analysis are summarized in Table 2.
Similar results were obtained using the 786-O cell lines
(data not shown). In summary, proper formation of tight
Knockdown of p27 disrupts VHL-mediated tight junction formation Figure 4
Knockdown of p27 disrupts VHL-mediated tight junction formation. (A) RCC10 cells stably expressing WT pVHL30 
were infected with retroviruses containing shRNA constructs directed at luciferase as control (sh Luc) or p27 (sh p27). 
Approximately 2 weeks post-infection, cell lysates were equally loaded and subjected to p27 and α-tubulin western blotting. 
(B) RCC10 WT VHL cells infected with shRNA to luciferase or p27 were grown to confluence on collagen I and photographed 
by digital phase microscopy (original magnification of 100×). (C) RCC10 WT VHL cells infected with shRNA to luciferase or 
p27 were grown to confluence on coverslips and immunostaining for ZO-1 (left panels) was performed (original magnification 
of 1000×). DAPI labeled nuclei of corresponding cells are also shown (right panels). (D and E) 786-O cells stably expressing 
pVHL19 were infected and analyzed as in (A) and (C).
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junctions appears to be severely compromised with VHL
type 1 mutants and the R167Q type 2B mutant, somewhat
aberrant with the Y98N type 2B mutant, and close to wild-
type with type 2A and 2C mutants, and thus seems to
loosely correspond with the risk of RCC associated with
these VHL disease subtypes [30].
To determine whether the VHL mutants varied in their
overall levels of ZO-1, a western blot was performed using
RCC10 lysates (Figure 9). ZO-1 levels were very slightly
upregulated in most type 1 VHL mutants as compared to
wild-type VHL-expressing cells. Moreover, two faster
migrating bands, perhaps representing ZO-1 cleavage
products, were detected at the greatest levels in type 1 VHL
mutant lysates and were absent in cells with wild-type
VHL. The significance of this observation is unclear, how-
ever the appearance of ZO-1 cleavage products in cells
challenged with apoptotic stresses has been associated
with impaired localization to tight junctions [76], which
agrees with the ZO-1 mislocalization seen in these type 1
VHL mutant cell lines. Extending these findings, one pos-
sibility is that the presence of these faster migrating ZO-1
bands indicates that type 1 VHL mutants are in a height-
ened state of cellular and/or metabolic stress, which has
been documented for VHL-negative cells [49,77].
HIF-2α plays a partial role in regulation of tight junctions
Our data had indicated that type 1 VHL mutants with high
levels of HIF-2α have dysregulated tight junctions. To
examine whether a direct link between HIF-α levels and
ZO-1 localization exists, we turned to a 786-O cell line in
which HIF-2α levels had been lowered by shRNA vectors
[47]. Note that 786-O cells have been reported to only
express the HIF-2α isoform [20]. We had previously com-
pared HIF-2α knockdown cells to parental cells, control
Additional RCC10 cell lines were generated Figure 5
Additional RCC10 cell lines were generated. (A) 
RCC10 VHL-null cells were stably transfected with pVHL30 
expression constructs. Cells were grown to confluence and 
prepared cell lysates were equally loaded and separated by 
SDS-PAGE. Western blots were performed for VHL, HIF-2α, 
and GLUT-1. α-tubulin was also assayed to demonstrate 
equal loading. (B) RCC10 VHL-null cells were stably infected 
with retroviruses containing mutant pVHL30 expression con-
structs (S65W, N78S, L158P) and assayed along with original 
control and WT VHL RCC10 cells as in (B).
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Type 1 VHL mutant proteins are unstable Figure 6
Type 1 VHL mutant proteins are unstable. (A) Indicated stably transfected RCC10 cell lines were incubated in media 
with no cycloheximide (0 time point) or with cycloheximide (100 μg/ml) for the indicated lengths of time. Cell lysates were 
prepared, equally loaded and subjected to VHL and α-tubulin western blotting. (B) Cycloheximide stability assay as in (A) was 
performed on the indicated stably infected RCC10 cell lines.
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infected cells, and those in which VHL had been stably
reintroduced [47]. In that study, it had been determined
that although regulation of cell cycle progression is
restored by HIF-2α knockdown, the morphology of the
cells was not restored to the full epithelial phenotype seen
with VHL re-expression [47]. In the current studies, a west-
ern blot for proteins associated with pVHL function was
performed (Figure 10). As previously, a decrease in HIF-
2α levels comparable to that seen with wild-type VHL
expression was observed with the shRNA (Figure 10A, top
panel). In agreement with prior cell cycle findings, HIF-2α
knockdown led to cyclin D1 downregulation and upregu-
lation of p27, also comparable to the effects of wild-type
VHL expression in these cells (Figure 10A, second and
third panels). Importantly, ZO-1 levels were slightly lower
in both wild-type VHL and HIF-2α knockdown cells (Fig-
ure 10A, second panel from the bottom), suggesting that
the minor differences in ZO-1 levels seen between cell
lines might be regulated by HIF-2α levels. Also, levels of
the potentially cleaved faster-migrating ZO-1 products
were greater in the parental and control infected cells than
in cells with wild-type VHL or HIF-2α shRNA (Figure 10A,
bottom panel), also suggesting that HIF-2α influences
these ZO-1 fragments. However, levels of these fragments
were slightly higher in HIF-2α knockdown cells than
those with wild-type VHL, indicating that formation of
this ZO-1 fragment may be only partially regulated by
HIF-2α.
We performed ZO-1 immunofluorescence with these cell
lines, to see if the differences in ZO-1 protein levels affect
tight junction formation (Figure 10B). The ZO-1 staining
pattern closely mirrored the western blot analysis: both
parental and control infected cells showed a disorganized
ZO-1 pattern, while cells with wild-type VHL displayed
abundant ZO-1 staining at cell-cell borders. HIF-2α
knockdown cells demonstrated partially restored ZO-1
staining, with more ZO-1 seen at cell-cell junctions in
comparison to the negative controls, but with a slightly
disorganized localization marked by incomplete and
somewhat jagged staining at some of the cell borders.
These results again indicate that tight junctions are par-
tially regulated by HIF-2α.
To see whether the observed differences in ZO-1 staining
are associated with changes in cell morphology, we cap-
tured phase-contrast images of these cells (Figure 10C). As
expected, 786-O cells stably expressing wild-type VHL had
a normal epithelial-like appearance marked by cobble-
stone shaped cells, while parental and control infected
cells showed a disorganized, fibroblastic morphology.
However, cells with HIF-2α knocked down also showed a
mostly disorganized phenotype, in spite of the observed
increase in ZO-1 staining at cell borders. Overall, these
results suggest that while HIF-α downregulation contrib-
utes to tight junction formation, this outcome is not suffi-
cient for cells to obtain the same epithelial morphology as
seen when VHL is reintroduced into these cells.
Discussion
In the present study, we have compared a panel of VHL
mutants that cover the spectrum of VHL disease subtypes
with respect to their ability to bring about the cell mor-
Differential regulation of key markers of VHL function by  type 1 and type 2 pVHL19 mutants in 786-O Figure 7
Differential regulation of key markers of VHL func-
tion by type 1 and type 2 pVHL19 mutants in 786-O. 
(A) 786-O cells were stably transfected with empty vector 
control or wild-type (WT) or mutant pVHL19 expression 
constructs, as indicated. Cells were grown to confluence on 
collagen I and prepared cell lysates were equally loaded and 
separated by SDS-PAGE. Western blots were performed for 
VHL, HIF-2α, GLUT-1, α5 integrin, cyclin D1, and α-tubulin. 
A faster migrating band is seen for del 114–178 upon darker 
exposure of the VHL blot (not shown). Quantification of the 
band intensities for the α5 integrin blot (as a percent of the 
band with greatest intensity) is provided at the bottom. (B) 
Indicated 786-O stable cell pools were grown to confluence 
on collagen I and photographed by digital phase microscopy 
(original magnification of 100×). Note the disorganized mor-
phology of the control and the VHL del 114–178 and RC161/
2QW-expressing cells.
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phological changes that are observed with wild-type VHL
in renal cells. We found that type 1 VHL mutants were
vastly deficient in producing an epithelial-like morphol-
ogy and higher levels of HIF-2α (and perhaps cyclin D1)
are likely to impact this phenotype. The disorganized
morphology of type 1 mutants was concomitant with a
lack of VHL protein stability and higher levels α5 integrin
(and for RCC10, β1 integrin). Moreover, the lack of epi-
thelial morphology seen with type 1 VHL mutants was
marked by aberrant localization of the tight junction
marker, ZO-1. Lowering of HIF-α levels was seen to greatly
influence tight junction formation, but was not sufficient
to bring about a full restoration of epithelial morphology.
The significance of these findings is further discussed
below.
In this report, we found that type 1 VHL mutants had con-
siderably elevated levels of HIF-2α. We analyzed VHL reg-
ulation of HIF-2α rather than HIF-1α because HIF-2α (but
not HIF-1α) is expressed in all of the RCC cell lines uti-
lized [20] and more importantly, HIF-2α is regarded as
the key HIF-α isoform in RCC formation [78,79]. While
type 1 VHL mutants were grossly deficient in their ability
to cause degradation of HIF-2α, the majority of type 2
mutations in this study were as efficient as wild type VHL,
regardless of their type 2 subtype. This result differs from
previous studies in which type 2B mutants were seen to be
deficient in HIF-2α ubiquitination [30,34]. The reasons
for the differences among these studies are currently
unclear and may relate to the levels of pVHL that result
from exogenous expression, as overexpression may com-
Contrasting regulation of tight junctions among VHL mutants of different disease types in RCC10 Figure 8
Contrasting regulation of tight junctions among VHL mutants of different disease types in RCC10. RCC10 cells 
lines (as indicated; all created by retroviral infection) were grown to confluence on coverslips and immunostaining for ZO-1 
(left panels) was performed (original magnification of 1000×). DAPI labeled nuclei of corresponding cells are also shown (right 
panels).
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pensate for incomplete loss of pVHL function with some
of the mutants but may not compensate for complete loss
of function.
Type 1 VHL mutants, in addition to defects in regulation
of HIF-2α, had lower levels of p27 in RCC10 cells as com-
pared to cells with wild-type VHL or type 2 mutants. One
exception was the reported type 1 mutant, L188Q, which
did not demonstrate lower p27 levels (and was also seen
to have intermediate phenotypes in a number of our
assays). Since the classification of L188Q as a type 1 muta-
tion is based on a single small family [29], it is possible
that this designation is incorrect. Notably, the downregu-
lation of p27 observed here with the other type 1 mutants
is opposite from a study in mouse embryo fibroblasts in
which loss of VHL led to p27 upregulation [80], which
may indicate that VHL's influence on p27 is cell-type
dependent. However, the decreased levels of p27 observed
with our type 1 VHL mutants are likely to be clinically rel-
evant since p27 is an effector of cell cycle withdrawal and
cell differentiation and low levels of p27 are associated
with poorly differentiated invasive tumors and a poor
prognosis in many epithelial cancers [81,82]. Moreover,
we observed that diminution of p27 levels disrupted tight
junction formation and epithelial cell morphology (to a
greater degree in RCC10 than 786-O). In RCC10 cells,
high p27 levels correlated well with low HIF-2α and cyclin
D1 levels, however VHL proteins that were able to prop-
erly regulate HIF-2α (including all type 2 VHL mutants)
were unable to produce changes in p27 abundance in
A498 cells, suggesting that p27 levels may be only indi-
rectly affected by HIF transcriptional activity and that VHL
might modulate p27 levels through some other mecha-
nism. Given that p27 is regulated at the transcriptional,
translational, and post-translational levels (reviewed in
[83]), the effect of pVHL on p27 levels warrants further
study.
Overall, the present findings indicate that the type 1 VHL
mutations (including missense mutations) represent a
more complete loss of VHL function as compared to the
type 2 mutations. Likely related to this loss of function,
proteins produced by type 1 VHL mutant cell lines were
shown to be very unstable as compared to the type 2
mutants. A number of the type 1 missense mutations con-
tain substitutions in amino acids whose side chains make
key contacts in pVHL folding [84], which can cause gross
misfolding or leave pVHL in an exposed, chaperonin-
bound state [85]. Some of the type 1 VHL mutant proteins
have also been shown to exhibit reduced binding to
elongin C, which is important for pVHL stability [30,53].
It is entirely possible that other type 1 missense muta-
tions, for which the relationship of the amino acid substi-
tution to pVHL folding is unclear from the present 3-
dimensional structure (such as S65W), will also show
impaired folding and that this defect may underlie the
more complete loss of function associated with type 1
mutations. Interestingly, one type 2B mutant, R167Q, was
unstable yet retained normal HIF-2α regulation in our
assays, signifying that deficiencies in stability and VHL
function are not synonymous. Again, it is probable that
overexpression of this mutant compensated for a partial
defect in ubiquitination function at steady-state levels.
However, the lack of stability observed for the R167Q
mutant indicates that considerable amounts of new pro-
tein synthesis may be necessary to attain this steady-state
level. At endogenous protein levels, a more noticeable,
but not complete loss of HIF-α regulation is likely to be
revealed for this mutant, as has been previously demon-
strated [30,34]. It is important to point out that the notion
that type 1 VHL mutants represent a greater loss of VHL
function than the type 2B mutations can be viewed as
somewhat inconsistent with the fairly equivalent high risk
of RCC among types 1 and 2B. However, it is possible that
in individuals with type 1 VHL mutations, higher levels of
HIF-2α and of the proapoptotic HIF target gene, EglN3,
cause some culling of renal cells upon loss of the wild type
allele, in a manner similar to as has been suggested for
pheochromocytoma [33]. Lending support to this
hypothesis, a recent report showed that mouse ES cells
homozygous for the type 2B R167Q mutation demon-
strate a growth advantage over VHL-null ES cells (i.e., a
type 1 mutant) in a teratoma xenograft assay [86], with
the HIF-2α profile of their cells paralleling those seen
here. More in vivo studies comparing the tumorigenic
events that occur with specific VHL mutants are necessary
to fully understand their differential risks of RCC.
Contrasting levels of ZO-1 fragments among VHL mutants of  different disease types in RCC10 Figure 9
Contrasting levels of ZO-1 fragments among VHL 
mutants of different disease types in RCC10. RCC10 
cells lines (as indicated; all created by retroviral infection) 
were grown to confluence. Cell lysates were prepared and 
equally loaded and separated by SDS-PAGE. Western blots 
were performed for ZO-1 and α-tubulin. Arrows indicate 
ZO-1 immunoreactive proteins.
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Although in our studies we did not observe major differ-
ences among the type 2 VHL mutants in RCC10 and 786-
O with respect to HIF-2α levels, p27 levels (in RCC10), or
cell morphological changes, there were some VHL-medi-
ated activities that seemed to more closely correlate with
VHL disease subtypes: localization of ZO-1 to cell-cell
junctions and regulation of α5 integrin levels (in 786-O).
There was a gradient in the degree of disruption of both of
these functions (i.e., absence of correct ZO-1 localization
to tight junctions and high levels of α5 integrin), with
type 1 VHL mutants being the most compromised, fol-
lowed in order by type 2B and type 2A, whereas type 2C
mutants behaved like wild-type. Thus, both α5 integrin
levels (in 786-O) and lack of ZO-1 regulation by VHL par-
allel the relative risk of RCC associated with the VHL dis-
ease subtypes of specific mutations: higher risk in types 1
and 2B, low risk in type 2A and no risk in type 2C
(reviewed in [2]). Although it is unclear whether integrin
levels and ZO-1 localization are regulated through similar
cellular pathways, it may be that cell-cell interactions and
cell-matrix interactions are coordinately regulated in a
VHL-dependent manner. It is worth noting that VHL activ-
ities independent of HIF-α ubiquitination are required for
both proper ZO-1 localization (shown here) and regula-
tion of α5 integrin levels [47,48]. One distinct possibility
is that the observed VHL-mediated ZO-1 localization and/
or integrin regulation is influenced by another reported
substrate for VHL ubiquitination, atypical protein kinase
C [87], for which roles in both tight junction formation
and integrin expression and adhesion have been demon-
strated [88-90]. However, HIF-α independent roles of
pVHL in cytoskeletal microtubule stability and extracellu-
lar matrix formation [41,43] might also impinge on ZO-1
and integrin regulation.
Whereas there is well-documented evidence that the loss
of HIF-α regulation upon VHL inactivation is critical for
RCC progression in VHL disease [35-38], it is unclear
whether HIF-α dysregulation is sufficient for the initiation
of renal tumors and/or cysts. Based on the data presented
Tight junctions are affected by levels of HIF-2α in 786-O Figure 10
Tight junctions are affected by levels of HIF-2α in 786-O. (A) Parental 786-O cells (786-O), 786-O cells stably trans-
fected with VHL (VHL +), and 786-O cells infected with an empty retrovirus (pSuperRetro) or infected with HIF-2α shRNAs 
(HIF2α shRNA), as described in [47], were grown for 1 week past confluence on collagen I coated culture dishes. Cell lysates 
were prepared, equally loaded, and western blotted for HIF-2α, cyclin D1, p27, α-tubulin and ZO-1 (both upper and lower 
immunoreactive species that were seen in Figure 9). (B) Indicated cell lines that were assayed in (A) were grown to confluence 
on coverslips and immunostained for ZO-1 (left panels; original magnification of 1000×). DAPI labeled nuclei of corresponding 
cells are also shown (right panels). (C) Indicated cell lines that were assayed in (A) and (B) were grown to confluence on colla-
gen I and photographed by digital phase microscopy (original magnification of 100×).
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in this report and elsewhere, we speculate that the proper
control of integrins and tight junctions may be important
for VHL tumor suppressor function at the early stages of
tumor formation. Integrins play key roles in cell adhesion
and migration, and can signal to pathways leading to cell
proliferation, invasion and survival (reviewed in [91]). α5
integrin has been shown to be expressed in clear cell renal
tumors and renal cysts, but not in normal proximal and
distal tubules [92], lending some import to the increased
α5 integrin levels seen here to correlate with VHL muta-
tions that have a higher RCC risk and suggesting that α5
integrin upregulation might be an early step in tumor ini-
tiation. The loss of tight junctions and associated cell-
polarity is also likely to be tumor promoting and might
also be an early step in tumor initiation, leading to an
ability of kidney epithelial cells to break free of cell-cell
contact restraints and to proliferate. Note that while these
studies reported here were being completed, Harten et al.
demonstrated that tight junctions are disrupted in both
RCC tumors and renal pre-malignant cystic lesions that
develop following VHL loss, supporting this notion [74].
Decreased expression of the adherens junction protein, E-
cadherin, following VHL loss [50,73] may further break
down cell-cell adhesion, aiding in tumor formation. How-
ever, the results of this study indicate that some additional
VHL function(s) may need to be lost for full epithelial to
mesenchymal transition, as noted below.
The present data shows that although there are VHL func-
tions independent of HIF-α regulation that impinge upon
aspects of cell morphology, HIF-α levels still have a large
influence on cellular morphological differentiation.
Along these lines, hypoxic conditions have been shown to
promote both an epithelial to mesenchymal switch and
loss of ZO-1 localization at cell-cell junctions of primary
renal tubule cells [51]. Here, high levels of HIF-2α corre-
lated well an undifferentiated fibroblastic cellular pheno-
type. However, shRNA knockdown of HIF-2α levels in
786-O cells, which has been shown to correct deficiencies
in E-cadherin expression [73] and here to promote ZO-1
localization to tight junctions, was not sufficient to revert
the cells to an epithelial morphology. The reasons for this
apparent paradox are not currently clear, but suggest that
some additional pVHL activity is necessary to bring about
the full epithelial morphology of cells. One remote possi-
bility, based on the findings of Harten et al. that knock-
down of HIF-1α restores tight junctions and cell
morphology more efficiently than knockdown of HIF-2α
[74], is that 786-O cells may express some residual HIF-1α
that maintains the fibroblastic appearance. Nonetheless,
other HIF-α independent pVHL functions, such as
integrin regulation and fibronectin deposition
[41,47,48,93] are likely to play roles mediating an epithe-
lial phenotype, since the interaction between integrins
and extracellular matrix does affect cell morphology
(reviewed in [91]). While further study may be necessary
to sort out the exact mechanisms by which pVHL regulates
an epithelial morphology, the current data supports the
supposition that both HIF-α dependent and HIF-α inde-
pendent pVHL activities are necessary for the regulation of
cell morphology.
Conclusion
Expression of Type 1 VHL mutants in RCC10 and 786-O
renal carcinoma cells failed to restore an epithelial mor-
phology, unlike wild type VHL and the majority of type 2
VHL mutants. Type 1 VHL mutants exhibited elevated lev-
els of HIF-2α, cyclin D1, α5 integrin, and lower levels of
p27 (in RCC10), and demonstrated protein instability
(which was also seen with the type 2B mutant R167Q).
Tight junctions, as visualized by ZO-1 immunostaining,
were most aberrant in type 1 VHL mutants, although tight
junction disorganization was seen with type 2B mutants
and to a lesser extent with type 2A mutants, but not with
type 2C. Knockdown of HIF-2α partially restored tight
junctions, but did not restore an epithelial morphology,
suggesting that VHL activities independent of HIF-α ubiq-
uitination are also needed for regulation of this cellular
phenotype. In conclusion, the data presented here high-
light several deficiencies in key effectors of cell cycle regu-
lation and cell-cell and cell-matrix associations in VHL
mutants (especially type 1), a combination of which are
likely to contribute to the initiation of VHL-associated
renal tumorigenesis.
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